Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

Heart Rhythm 2006 Aug 9;3(8):881-6. Epub 2006 May 9.

Division of Cardiology, Section of Electrophysiology, Emory University, Atlanta, Georgia 30322, USA.

Background: Inflammation and oxidative stress have been implicated in the pathogenesis of atrial fibrillation (AF). Lipid-lowering drugs, particularly statins and fibrates, possess anti-inflammatory and antioxidant properties.

Objectives: The purpose of this study was to assess the impact of lipid-lowering drug use on AF prevalence in patients with reduced left ventricular ejection fraction (LVEF).

Methods: Data were obtained from ADVANCENT(SM), a multicenter registry of patients with reduced LVEF (
Results: Of the 25,268 patients, 71.3% had hyperlipidemia, and 66.8% were prescribed lipid-lowering drugs. AF prevalence was 25.1% in patients taking lipid-lowering drugs compared with 32.6% in untreated hyperlipidemic patients and 32.8% in patients without hyperlipidemia (P <.001 for both comparisons). In multivariable analysis, lipid-lowering drug use remained significantly associated with reduced odds of AF (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.64-0.74), and this effect was larger than that of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR 0.85, 95% CI 0.79-0.92) or beta-blockers (OR 0.95, 95% CI 0.88-1.02). The beneficial impact of lipid-lowering drugs on AF risk was independent of their effects on the lipid profile. In patients in whom data on specific lipid-lowering drugs were available, 92% of the patients undergoing lipid-lowering therapy received statins, and 98% received statins and/or fibrates.

Conclusion: Use of lipid-lowering drugs in patients with reduced LVEF is associated with a significant reduction in the prevalence of AF independent of the lipid profile and other known arrhythmia risk factors. This effect is larger than that of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or beta-blockers and may be the result of the antioxidant and anti-inflammatory effects of statins and fibrates.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hrthm.2006.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164215PMC
August 2006

Publication Analysis

Top Keywords

atrial fibrillation
8
patients reduced
8
left ventricular
8
lipid-lowering drug
8
drugs statins
4
fraction lvefmethods
4
lipid-lowering drugs
4
statins fibrates
4
fibrillation lipid-lowering
4
stress implicated
4
data advancentsm
4
implicated pathogenesis
4
pathogenesis atrial
4
fibrates possess
4
lvefmethods data
4
anti-inflammatory antioxidant
4
study assess
4
reduced left
4
assess impact
4
impact lipid-lowering
4

Similar Publications